Patents by Inventor Brian Richard MacDonald

Brian Richard MacDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
    Patent number: 11813257
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: November 14, 2023
    Assignee: Disc Medicine, Inc.
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
    Publication number: 20210283129
    Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 16, 2021
    Inventors: Brian Richard MacDonald, Maria Gabriela Beconi, Vu Hong
  • Method of treating immune cell mediated systemic diseases
    Publication number: 20010056066
    Abstract: An improved method of treating immune cell mediated systemic diseases, particularly T and B cell mediated diseases, is provided by increasing the systemic exposure, or bioavailibility, of a therapeutic protein. Such therapeutic protein is selected from the group consisting of a monoclonal antibody, a soluble receptor and a soluble ligand which binds to an antigen expressed on the surface of an immunce cell.
    Type: Application
    Filed: July 13, 2001
    Publication date: December 27, 2001
    Applicant: SmithKline Beecham Corporation
    Inventors: Peter John Bugelski, Charles Baldwin Davis, Brian Richard MacDonald